Survival outcome of neoadjuvant endocrine therapy plus trastuzumab and pertuzumab (ET plus T plus P) vs. de-escalated chemotherapy (CT) plus T plus P in hormone receptor positive (HR+)/HER2+early breast cancer (EBC): WSG-TP-II trial

被引：0

作者：

Gluz, O. ^{[1
]}

Nitz, U. A. ^{[2
]}

Christgen, M. ^{[3
]}

Kummel, S. ^{[4
]}

Holtschmidt, J. ^{[5
]}

Schumacher, J. ^{[6
]}

Hartkopf, A. D. ^{[7
]}

Luedtke-Heckenkamp, K. ^{[8
]}

Just, M. ^{[9
]}

von Schumann, R. ^{[10
]}

Polata, S. ^{[11
]}

Schinkoethe, T. ^{[12
]}

Graeser-Mayer, M. K. ^{[13
]}

Kates, R. E. ^{[14
]}

Wuerstlein, R. ^{[15
]}

Kreipe, H. ^{[3
]}

Harbeck, N. ^{[16
]}

机构：

[1] Evangeliches Krankenhaus Bethesda Klin, Breast Ctr, Monchengladbach, Germany

[2] West German Study Grp, Senol, Monchengladbach, Germany

[3] MHH, Pathol, Hannover, Germany

[4] Kliniken Essen Mitte Evang Huyssens Stiftung, Breast Unit, Essen, Germany

[5] St Elisabeth Clin Hohenlind, Breast Ctr, Cologne, Germany

[6] Palleos GmbH, Stat, Wiesbaden, Germany

[7] Univ Hosp Tubingen, Ctr Womens Hlth, Tubingen, Germany

[8] Niels Stensen Kliniken GmbH, Franziskus Hosp Harderberg, Oncol Dept, Georgsmarienhutte, Germany

[9] Onkol Schwerpunkt Praxis, Oncol, Greifswald, Germany

[10] Johanniter Bethesda Moenchengladbach, Breast Ctr Niederrhein, Monchengladbach, Germany

[11] Oncol Ctr Spandau, Oncol, Berlin, Germany

[12] LMU Klinikum Univ Munchen, Breast Ctr, Munich, Germany

[13] Westdeutsch Studiengrp GmbH, Senol, Monchengladbach, Germany

[14] Westdeutsch Studiengrp GmbH, Breast Ctr Dept, Monchengladbach, Germany

[15] LMU Klinikum Univ Munchen, Breast Ctr Dept, Munich, Germany

[16] LMU Univ Hosp, Dept Obstet & Gynecol, Breast Ctr, Munich, Germany

来源：

ANNALS OF ONCOLOGY | 2024年 / 35卷

关键词：

D O I：

10.1016/j.annonc.2024.08.2255

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LBA17

引用

页码：1210 / 1210

页数：1

共 50 条

[21] Interim Results of BACH: Randomized Phase II Trial Evaluating the Safety of Two Chemotherapy Regimens as Adjuvant Therapy in Patients with HER2-Positive Breast Cancer: PLD plus Cyclophosphamide plus Trastuzumab (PLD plus C plus H), or Doxorubicin plus Cyclophosphomide (A plus C), Each Followed by Paclitaxel plus Trastuzumab (T plus H)
Rayson, D.
Suter, T.
van der Vegt, S.
Jackisch, C.
Lluch, A.
van den Bosch, J.
Vivanco, Lopez G.
Van Gent, Mathilde A.
Wildiers, H.
Provencher, L.
Stopatschinskaja, S.
Srinivasan, S.
Richel, D.
CANCER RESEARCH, 2009, 69 (24) : 620S - 620S
[22] Long-term outcomes of neoadjuvant trastuzumab emtansine plus pertuzumab (T-DM1+P) and docetaxel plus carboplatin plus trastuzumab plus pertuzumab (TCbHP) for HER2-positive primary breast cancer: results of the randomized phase 2 JBCRG20 study (Neo-peaks)
Takano, Toshimi
Masuda, Norikazu
Ito, Mitsuya
Inoue, Kenichi
Tanabe, Yuko
Kawaguchi, Kousuke
Yasojima, Hiroyuki
Bando, Hiroko
Nakamura, Rikiya
Yamanaka, Takashi
Ishida, Kazushige
Aruga, Tomoyuki
Yanagita, Yasuhiro
Tokunaga, Eriko
Aogi, Kenjiro
Ohno, Shinji
Kasai, Hiroi
Kataoka, Tatsuki R.
Morita, Satoshi
Toi, Masakazu
BREAST CANCER RESEARCH AND TREATMENT, 2024, 207 (01) : 33 - 48
[23] Final analysis of WSG-ADAPT HER2+/HR+ phase-II-trial - efficacy, safety and predictive markers for 12-weeks of neoadjuvant T-DM1 with or without endocrine therapy versus Trastuzumab plus endocrine therapy in HER2-positive hormone-receptor-positive early breast cancer
Braun, M.
Gluz, O.
Nitz, U.
Christgen, M.
Kuemmel, S.
Schumacher, C.
Potenberg, J.
Kraemer, S.
Kleine-Tebbe, A.
Augustin, D.
Aktas, B.
Forstbauer, H.
Tio, J.
Liedtke, C.
Kates, R. E.
Wuerstlein, R.
Kreipe, H. -H.
Harbecks, N.
ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 2 - 2
[24] Interim overall survival analysis of APHINITY (BIG 4-11): A randomized multicenter, double-blind, placebo-controlled trial comparing chemotherapy plus trastuzumab plus pertuzumab versus chemotherapy plus trastuzumab plus placebo as adjuvant therapy in patients with operable HER2-positive early breast cancer
Piccart, Martine
Procter, Marion
Fumagalli, Debora
de Azambuja, Evandro
Clark, Emma
Ewer, Michael S.
Restuccia, Eleonora
Jerusalem, Guy
Dent, Susan
Reaby, Linda
Bonnefoi, Herve
Krop, Ian
Liu, Tsang-Wu
Pienkowski, Tadeusz
Toi, Masakazu
Wilcken, Nicolas
Andersson, Michael
Im, Young-Hyuck
Tseng, Ling-Ming
Lueck, Hans-Joachim
Colleoni, Marco
Monturus, Estefania
Sicoe, Mihaela
Guillaume, Sebastien
Bines, Jose
Gelber, Richard
Viale, Giuseppe
Thomssen, Christoph
CANCER RESEARCH, 2020, 80 (04)
[25] Biomarker analysis from KAITLIN, a randomised phase III study of adjuvant trastuzumab emtansine (TDM-1; K) plus pertuzumab (P) versus trastuzumab (H) plus taxane (T) plus P after anthracyclines (AC) for high-risk HER2-positive early breast cancer (EBC)
Metzger, O.
Lambertini, C.
Krop, I. E.
Phillips, G. Lewis
Perou, C. M.
Symmans, F.
Melero, I.
Harbeck, N.
Winer, E. P.
Im, S-A.
Barrios, C. H.
Bonnefoi, H.
Gralow, J. R.
Ellis, P. A.
Gianni, L.
Toi, M.
Swain, S. M.
Boulet, T.
Song, C.
de Haas, S.
ANNALS OF ONCOLOGY, 2021, 32 : S37 - S38
[26] Final analysis of WSG-ADAPT HER2+/HR+ phase II trial: Efficacy, safety, and predictive markers for 12-weeks of neoadjuvant TDM1 with or without endocrine therapy versus trastuzumab plus endocrine therapy in HER2-positive hormone-receptor positive early breast cancer
Harbeck, N.
Gluz, O.
Christgen, M.
Braun, M.
Kuemmel, S.
Schumacher, C.
Potenberg, J.
Kraemer, S.
Kleine-Tebbe, A.
Augustin, D.
Aktas, B.
Forstbauer, H.
Tio, J.
Liedtke, C.
Kates, R. E.
Wuerstlein, R.
de Haas, S. L.
Kiermaier, A.
Kreipe, H. H.
Nitz, U.
CANCER RESEARCH, 2016, 76
[27] Results of multicenter phase II WSG Neo-Predict trial: Predictive markers for evaluation of response to neoadjuvant paclitaxel plus trastuzumab plus lapat in HER2-positive early breast cancer.
Eichler, Christian
Gluz, Oleg
Nitz, Ulrike
Christgen, Matthias
Krabisch, Petra
Hackenberg, Reinhard
Skrobol, Markus
Mobus, Volker
Kates, Ronald
Schumacher, Johannes
Kreipe, Hans Heinrich
Harbeck, Nadia
Warm, Mathias
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[28] NATALEE: Phase III study of ribociclib (RIBO) plus endocrine therapy (ET) as adjuvant treatment in hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) early breast cancer (EBC).
Slamon, Dennis J.
Fasching, Peter A.
Patel, Ravindranath
Verma, Sunil
Hurvitz, Sara A.
Chia, Stephen K. L.
Crown, John
Martin, Miguel
Barrios, Carlos H.
Spera, Gonzalo
Lopez, Celine
Hor, Ines
Pelov, Diana
Hughes, Gareth
Nawinne, Moditha
Hortobagyi, Gabriel N.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[29] Primary analysis of KAITLIN: A phase Ill study of trastuzumab emtansine (T-DM1) + pertuzumab versus trastuzumab plus pertuzumab plus taxane, after anthracyclines as adjuvant therapy for high-risk HER2-positive early breast cancer (EBC).
Harbeck, Nadia
Im, Seock-Ah
Barrios, Carlos H.
Bonnefoi, Herve R.
Gralow, Julie
Toi, Masakazu
Ellis, Paul
Gianni, Luca
Swain, Sandra M.
Im, Young-Hyuck
De Laurentiis, Michelino
Nowecki, Zbigniew
Shah, Jigna
Boulet, Thomas
Liu, Haiying
Macharia, Harrison
Trask, Peter
Song, Chunyan
Winer, Eric P.
Krop, Ian E.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[30] Ribociclib (RIB) plus endocrine therapy (ET) in Japanese women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC)
Masuda, N.
Noguchi, S.
Ishikawa, T.
Aruga, T.
Kim, S. J.
Toyama, T.
Saeki, T.
Saito, M.
Yamanaka, T.
Watanabe, J.
Nakamura, S.
Takahashi, M.
Inoue, K.
Gounaris, I.
Han, Y.
Samant, T. S.
Gazdoiu, M.
Ito, Y.
ANNALS OF ONCOLOGY, 2018, 29

← 1 2 3 4 5 →